NCT03772405

Effect of the Nasal Gel "Nascum®-Plus" on Allergic Symptoms

Cross Over Study to Assess the Effect of the Nasal Gel "Nascum®-Plus" on Allergic Symptoms and Inflammatory Cells and Cytokines During and After Allergen Challenge in the Fraunhofer Allergen Challenge Chamber (ACC)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Fraunhofer-Institute of Toxicology and Experimental Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to assess if a physical barrier, created by the nasal gel Nascum®- Plus, is able to prevent or minimize the induction of nasal symptoms during allergen challenge in the Fraunhofer Allergen Challenge Chamber (ACC). Furthermore, the effect on soluble and cellular inflammatory markers induced by the allergic reaction will be assessed. Nascum®-Plus contains no active pharmaceutical ingredient, only monographed pharmaceutical excipients.

Conditions

• Rhinitis, Allergic, Seasonal

Interventions

Type	Name	Description
DRUG	Nascum Plus	nasal application of nascum plus
OTHER	ACC	4 hours challenge to grass pollen in the allergen challenge chamber (ACC)

Timeline

• Start date: 2018-12-12
• Primary completion: 2019-02-01
• Completion: 2019-02-01
• First posted: 2018-12-11
• Last updated: 2019-02-15

Locations

1 site across 1 country: Germany